People treated with oral semaglutide 25 mg and 50 mg experienced a superior weight loss of 6.7 kg and 8.0 kg, respectively, compared with a reduction of 4.4 kg with oral semaglutide 14 mg.

Source Reference: Aroda VR, et al "Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised ...

Serious adverse events were less common with oral semaglutide 14 mg (47.9%) than with placebo (50.3%), although there was a higher incidence of gastrointestinal disorders with oral semaglutide 14 ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...

A new study found that once-daily oral semaglutide taken at 25 milligrams (mg) and 50 mg did a better job in lowering blood sugar levels and promoting weight loss than the lowest dose of 14 mg ...

At the end of the 52 weeks, the participants who took 50 mg of oral semaglutide had lost, on average, 17.5 pounds. Those who took 25 mg and 14 mg lost about 14.8 pounds and 10 pounds, respectively.

In STEPs 2 and 4, the estimated treatment differences between the semaglutide 2.4-mg and placebo arms were −6.2% and −14.8%, respectively.

In the double-blind phase IIIb trial, adults on 2.0 mg of once-weekly injectable semaglutide had a 2.1% mean drop in baseline HbA1c over 40 weeks of treatment versus a 1.9% reduction in those on 1 ...

Adults assigned 2 mg semaglutide also had a mean weight loss of 14.1 lb at 40 weeks compared with a mean weight loss of 12.5 lb with 1 mg semaglutide.

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse ...